SGO 2022 Conference Coverage on VuMedi
Playback speed
10 seconds
SGO 2022 Final OS Results From SOLO3: Phase III Trial Assessing Olaparib Monotherapy vs. Non-Platinum Chemo in Heavily Pretreated Patients With Germline BRCA1 and/or BRCA2m Platinum-Sensitive Relapsed Ovarian Cancer
By
SGO 2022 Conference Coverage on VuMedi
FEATURING
Richard Penson
By
SGO 2022 Conference Coverage on VuMedi
FEATURING
Richard Penson
337 views
April 7, 2022
Comments 0
Login to view comments.
Click here to Login
Videos